Conclusion
tumors
REGRESSION, TUMORS
This study did not meet the primary endpoint (PFS6); however, we found that immune signatures were significantly upregulated in the tumors with regression upon GC1118 therapy, which signifies the potential of immune‐mediated antitumor efficacy of GC1118.
[Correction added on August 24, 2023 after first online publication. The author Seung‐Won Choi’s present address has been included in this version.]Seung Won Choi and Hyun Ae Jung contributed equally to this work.